Enanta Pharma (ENTA) Misses Q4 EPS by 27c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Enanta Pharmaceuticals Reports Financial Results for its Fourth Quarter and Year Ended September 30, 2017
November 20, 2017 4:01 PM ESTWebcast and Conference Call today at 4:30 p.m. ET
Cash and marketable securities totaled $293.7 million at September 30, 2017 Total revenue for the quarter was $75.9 million Milestone payments totaling $65.0 million received following AbbVies U.S. approval of MAVYRET (glecaprevir/pibrentasvir) and EU approval of MAVIRET (glecaprevir/pibrentasvir) Positive Phase 1 results for EDP-305 support further clinical evaluation in PBC and NASH patients Fast Track designation granted to EDP-305 by the U.S. FDA for the treatment of patients with primary... More